Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Baicalin injection with anti-influenza virus effect

An anti-influenza virus and glycoside injection technology, applied in the field of baicalin injection, can solve the problems of high price, low oral availability, small distribution volume, etc., and achieve the effect of rapid onset of action, high bioavailability, and prolonged survival time

Inactive Publication Date: 2014-04-16
CHINA PHARM UNIV
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical use of zanamivir and oseltamivir has certain limitations, such as the low oral availability of zanamivir, small volume of distribution in the body, and rapid renal clearance, so it can only be used as a local drug; As an anti-influenza specific drug, Weiwei (trade name Tamiflu) has withstood the double tests of avian influenza and H1N1 influenza, but due to its high price, it is difficult to promote in developing countries, and the emergence of a large number of drug-resistant virus strains in clinical practice is also a problem. has been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Baicalin injection with anti-influenza virus effect
  • Baicalin injection with anti-influenza virus effect
  • Baicalin injection with anti-influenza virus effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Inhibitory effect of baicalin injection on MDCK cells infected by influenza A virus A / FM / 1 / 47(H1N1) and A / Beijing / 32 / 92(H3N2) and the effect on cell survival rate

[0020] Experimental settings Normal control group, virus control group, positive drug oseltamivir 4 μg / ml, ribavirin group 2 μg / ml and baicalin group 80 μg / ml, 60 μg / ml, 40 μg / ml, 30 μg / ml, 20 μg / ml ml. MDCK cells by 5×10 4 Inoculate a 96-well culture plate at a concentration of / ml, 100 μl per well, and store at 37°C in 5% CO 2 Cultured in the incubator for 24h to form a cell monolayer. After discarding the supernatant, add 100TCID 50 Infection cells with influenza virus A / FM1 / 1 / 47 (H1N1) or A / Beijing / 32 / 92 (H3N2), incubated at 37°C for 2 hours, removed the virus liquid, and added different concentrations of baicalin 80 μg / ml, 60 μg / ml ml, 40 μg / ml, 30 μg / ml, 20 μg / ml and positive control drug ribavirin group 2 μg / ml, oseltamivir group 4 μg / ml maintenance medium, normal control group and virus control g...

Embodiment 2

[0025] Effect of Baicalin Injection on the Death Protection Rate of Influenza A Virus A / FM / 1 / 47(H1N1) Infected Mice

[0026] The experiment used 17-20g ICR mice, which were randomly divided into 6 groups, which were set as normal control group, virus control group, oseltamivir 100mg / kg / d, ribavirin 100mg / kg / d and baicalin Low-dose group 50mg / kg / d, medium-dose baicalin 100mg / kg / d, high-dose baicalin group 200mg / kg / d. After 7 days of adaptive culture, the experiment was started. Except for the normal control group, mice in other groups were lightly anesthetized with ether, and inoculated into the nasal cavity equivalent to 8LD 50The allantoic fluid of chicken embryos containing influenza virus was 50 μl per chick, and the oseltamivir group was administered intragastrically 1 hour after infection, once a day, 0.2ml once a day, for a total of 5 days. The ribavirin group and the baicalin administration group were administered through the tail vein 1 hour after infection, and then...

Embodiment 3

[0033] Protective Effect of Baicalin Injection on Body Weight of Influenza A Virus A / FM / 1 / 47(H1N1) Infected Mice

[0034] After the virus infected mice, it caused viral pneumonia in mice, resulting in poor breathing, reduced food intake, and weight loss in mice. Weight protection is a useful apparent indicator for evaluating the inhibition of drugs on virus proliferation in vivo. Experimental results ( Figure 5 ) showed that, except for the mice in the normal group, the mice in the other groups began to lose weight and disease symptoms on the 3rd day, manifested as shrugging hair, eating poorly, becoming thin, curled up to avoid the cold, etc. The body weight of mice in the virus group decreased the most. Since baicalin, ribavirin and oseltamivir inhibited the proliferation of the virus in the lungs of mice, the body weight of mice in each administration group decreased more than that of the virus group. Small, all showed the effect of protecting the body weight of mice to a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a baicalin injection with anti-influenza virus effect, which is prepared from baicalin weighed according to required volume and set concentration, 0.6g of sodium dihydrogen phosphate, 2.16g of disodium hydrogen phosphate and 100ml of injection water through high-temperature high-pressure sterilization, wherein the pH value of sodium hydroxide is regulated to 7.0. The medicine has a remarkable advantages of in-vivo and in-vitro anti-influenza virus activity, high bioavailability, small side effect and adverse response and the like, has the effect of inhibiting neuraminidase activity to stop virus release, has unique advantages and wide development prospect in the field of preventing and treating influenza virus.

Description

technical field [0001] The invention relates to a baicalin injection having an anti-influenza virus effect, and the baicalin is dissolved in a phosphate buffer solution. Background technique [0002] Influenza is an acute respiratory infectious disease caused by influenza virus that seriously threatens human life and health. It is highly contagious, has a short incubation period, and has a high incidence rate. It is the first infectious disease to be monitored globally. cannot yet be fully controlled. Influenza is mainly transmitted through close-range air droplets, and can also be transmitted through direct or indirect contact with mucous membranes in the mouth, nasal cavity, eyes, etc. Influenza symptoms are mostly manifested as chills and high fever, accompanied by headache, muscle and joint pain, extreme fatigue, loss of appetite and other systemic symptoms, often with sore throat, dry cough, runny nose and other symptoms of upper respiratory tract infection. Respirato...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K31/7048A61P31/16
Inventor 周长林窦洁丁玥郁洁王慧郭青龙尤启冬
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com